App-Quantinova.ai

HIBISCUS, AN ADAPTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF ORAL FT-4202, A PYRUVATE KINASE ACTIVATOR IN PATIENTS WITH SICKLE CELL DISEASE

Kenneth Ataga - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Sickle cell anemia

Hydroxyurea

SUPERIOR OUTCOMES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST REMISSION FOR NPM1/FLT3-ITD MUTATED AML

Callum Wright - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

L-Tyrosine

SAFETY AND EFFICACY OF MEPOLIZUMAB IN HYPEREOSINOPHILIC SYNDROME: AN OPEN-LABEL EXTENSION STUDY

Florence Roufosse - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hypereosinophilic Syndrome

Mepolizumab

KTE-X19 VERSUS STANDARD OF CARE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH BRUTON TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM EUROPE

Georg Hess - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

L-Tyrosine

A RETROSPECTIVE TWO-CENTRE COHORT STUDY OF THE EFFICACY AND SAFETY OF DARATUMUMAB WITH BORTEZOMIB AND DEXAMETHASONE THERAPY FOR PREVIOUSLY TREATED MULTIPLE MYELOMA

Irene Sanchez - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

AGEING MIMICS LEUKEMIC ADAPTATION OF BONE MARROW STROMAL CELLS AND PROMOTES ACUTE MYELOID LEUKEMIA INITIATION

Xiying Ren - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

EFFICACY AND SAFETY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE BASED ON REFRACTORY STATUS TO LENALIDOMIDE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE BOSTON STUDY

Xavier Leleu - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY

Rogier Mous - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

N/A

CLINICAL IMPACT OF RECURRENT GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY

Larry Mansouri - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

TP53

PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA STUDY)

Stephen Opat - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mucosa-associated lymphoid tissue lymphoma

Ibrutinib

LATE-ONSET VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED PATIENTS FROM THE EBMT PASS REGISTRY STUDY

Mohamad Mohty - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic veno-occlusive disease with immunodeficiency

Defibrotide

ISOFORM-SPECIFIC AND SIGNALING-DEPENDENT PROPAGATION OF ACUTE MYELOID LEUKEMIA BY WILMS TUMOR 1

Constanze Bonifer - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

AN EPIDEMIOLOGICAL STUDY OF THE CARDIOVASCULAR HEALTH AND THROMBOTIC RISK PROFILES OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS IN PRIMARY CARE ACROSS THE UNITED KINGDOM

Frederick Chen - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

EFFECT OF OLUTASIDENIB (FT-2102) ON COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MUTANT IDH1 ACUTE MYELOID LEUKEMIA. RESULTS FROM A PLANNED INTERIM ANALYSIS OF A PHASE 2 CLINICAL TRIAL

Stphane de Botton - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

FT-2102

IBRUTINIB TREATMENT IN THE FIRST-LINE SETTING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: UP TO 7 YEARS OF FOLLOW-UP IN THE RESONATE-2 STUDY

Paolo Ghia - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

chlorambucil

INTER-B NHL RITUX 2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN’S LYMPHOMA/ACUTE LEUKAEMIA: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY.

Veronique Minard-Colin - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

Rituximab

A COMPARISON OF CLINICAL OUTCOMES FROM ZUMA-5 (AXICABTAGENE CILOLEUCEL) AND THE INTERNATIONAL SCHOLAR-5 EXTERNAL CONTROL COHORT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)

Paola Ghione - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Axicabtagene ciloleucel

PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Lindsey Roeker - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

David Marks - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

PROGNOSTIC FACTORS OF OVERALL AND RELAPSE-FREE SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION: MULTIVARIATE ANALYSES FROM THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE (ORAL-AZA )

Gail Roboz - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Vidaza

Filters

45280 Abstracts